Early human trials in people with obesity found that daily AOD9604 was well tolerated and had a safety profile similar to placebo, with no major effects on glucose metabolism or IGF1, though weightloss results were modest and inconsistent
Our take: TB-500 is a reasonable option for people dealing with diffuse or hard-to-localize soft-tissue injuries where the goal is systemic mobilization of repair signals rather than a targeted local intervention
Most treatment plans involve: Daily injections Cycles lasting 48 weeks Followed by reassessment The exact frequency depends on physician guidance and your regenerative goals
Presented for research literature review only Chang CH et al
Category 2 placement: The FDA placed Epitalon in Category 2 of the 503A list, citing significant safety concerns
Key Takeaways Recovery, not magic: peptides for athletes are studied mainly for tissue repair and recovery support, not as a shortcut to performance gains